Decera Clinical Education Infectious Disease Podcast

In this podcast, Dr Dominique Laurent Braun discusses his micro-elimination program, the Swiss HCVree trial, designed to prevent hepatitis C virus (HCV) transmission among HIV-positive men who have sex with men. The study employed a test-and-treat approach to eliminate HCV infection in this key target population and could be a model for other countries to eliminate HCV infection in certain populations.Presenter:Dominique Laurent Braun, MDSenior Staff PhysicianDivision of Infectious Diseases and Hospital Epidemiology, University Hospital ZurichUniversity of ZurichZurich, SwitzerlandContent based on an online CME program supported by independent educational grants from AbbVie and Gilead Sciences.Link to full program: https://bit.ly/3OGHvOv Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Antiviral agents continue to be effective against different strains of SARS-CoV-2 when used early in the disease course. In this episode, learn about the role of antiviral agents in hospitalized and high-risk nonhospitalized patients with COVID-19 and in different age groups. Listen as David A. Wohl, MD, discusses when and how to use IV and oral antiviral agents including:Nirmatrelvir + ritonavirRemdesivirMolnupiravirPresenter:David A. Wohl, MDProfessor of MedicineSchool of MedicineSite Leader, Global Infectious Diseases Clinical Trials UnitUniversity of North Carolina at Chapel HillChapel Hill, North CarolinaReview the downloadable slidesets at:https://bit.ly/3Ou4tbELink to full program: https://bit.ly/3EBdf38 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The place of monoclonal antibodies in COVID-19 is changing. In this episode, learn about their role in prophylaxis of patients who are at high risk of complications from acquiring COVID-19 or treatment of high-risk patients who have a mild to moderate COVID-19 infection. Listen as Gregory Huhn, MD, MPHTM, discusses when and how to use monoclonal antibodies including:BebtelovimabCilgavimab/tixagevimabSotrovimabPresenter:Gregory Huhn, MD, MPHTMAssociate ProfessorDepartment of Infectious DiseasesRush University Medical CenterSenior Director of HIV ServicesDepartment of Infectious DiseasesCook County HealthChicago, IllinoisReview the downloadable slidesets at: https://bit.ly/3xOfu1ALink to full program: https://bit.ly/3EBdf38 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Oluwaseun Falade-Nwulia, MBBS, MPH, and a patient with previous injection drug use who has been cured of HCV infection discuss critical barriers that are preventing more people with current or previous injection drug use from receiving appropriate HCV care.This insightful discussion underscores the negative effects of stigma toward people who inject drugs that exist in many clinical settings, the important role that socioeconomic factors such as transportation access and stable housing play in preventing access to HCV care, the effects of insufficient staffing at many addiction treatment centers, and the need for creative solutions to overcome these barriers.Presenter:Oluwaseun Falade-Nwulia, MBBS, MPH Associate ProfessorDivision of Infectious DiseasesJohns Hopkins University School of MedicineAttendingDivision of Infectious DiseasesJohns Hopkins HospitalBaltimore, MarylandContent based on an online CME program supported by independent educational grants from AbbVie and Gilead Sciences, Inc. and developed in collaboration with the American Liver Foundation.Link to full program:https://bit.ly/3KmJvZt Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Renslow Sherer, MD, discusses what is known to date regarding long COVID, also known as postacute sequelae of COVID-19 infection, including:Possible causes and risk factorsSigns and symptomsClinical managementTreatment options under considerationRole of vaccinationPresenter: Renslow Sherer, MDDirector, International HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisReview the downloadable slideset and the full program at: https://bit.ly/3Ix8uZg Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In episode 7 of a series of sharing sessions between a physician and patient, Ming-Lung Yu, MD, PhD, and his patient, who is living with chronic hepatitis B, discuss:Role of family history in risk of hepatocellular carcinoma (HCC)Surveillance for HCCSteps to take when diagnosed with HCCHow to live a healthy life after HCC diagnosis and treatmentPresenter: Ming-Lung Yu, MD, PhDChair ProfessorHepatobiliary DivisionDepartment of Internal Medicine and Hepatitis CenterKaohsiung Medical UniversityVisiting StaffHepatobiliary DivisionDepartment of Internal MedicineKaohsiung Medical University HospitalKaohsiung City, TaiwanContent based on an online CME program supported by an independent educational grant from Gilead Sciences.Link to full program:https://bit.ly/37GY0cm Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Anti-inflammatory agents and immunomodulators are key components to treating patients who are severely or critically ill due to a COVID-19 infection.In this episode, Vikramjit Mukherjee, MD, discusses the role and timing of these treatment options, including:High-titer convalescent plasmaCorticosteroidsInterleukin-6 inhibitors (eg, tocilizumab)Janus kinase inhibitors (eg, baricitinib)Presenter:Vikramjit Mukherjee, MDAssistant Professor of MedicineDivision of Pulmonary, Critical Care, & Sleep MedicineNew York University School of MedicineDirector, Medical Intensive Care UnitBellevue HospitalNew York, New York Review the downloadable slidesets at: https://bit.ly/35NNb7QLink to full program: https://bit.ly/35SrxQ0 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode from the series “Key Decisions in HIV Care,” Cristina Mussini, MD, and William R. Short, MD, MPH, AAHIVS, discuss important considerations for ART with opportunistic infections, including: When to start ART with pneumocystis pneumonia including discussion of the ACTG 5164 study of immediate vs delayed ART with opportunistic infectionsEACS, DHHS, and IAS-USA guideline recommendations for starting ART in the setting of most opportunistic infectionsConsiderations for the administration of ART to patients who are unable to swallow or critically ill and intubatedTreatment of Kaposi sarcoma and considerations for starting ART to avoid drug–drug interactions with Kaposi sarcoma treatmentConsiderations for starting ART with cytomegalovirus and the risk for IRIS from cytomegalovirusDiscussion of treatment of cytomegalovirus and overlapping toxicities between its treatment and ARTWhen to start ART with cryptococcal meningitis and the data to support delayed treatment initiation with this particular opportunistic infectionEACS, DHHS, and IAS-USA guideline recommendations for starting ART in the setting of cryptococcal meningitis specificallyTreatment of cryptococcal meningitis and managing drug–drug interactions between ART and antifungal therapyPresenters:Cristina Mussini, MDHead of Department of Infectious Diseases and Tropical MedicineFull Professor of Infectious DiseasesInfectious Diseases Clinics University HospitalUniversity of Modena and Reggio EmiliaReggio Emilia, Italy William R. Short, MD, MPH, AAHIVSAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicinePerelman School of Medicine at the University of PennsylvaniaPhiladelphia, Pennsylvania Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.Follow along with the slides at:https://bit.ly/3uktrm1Link to full program:https://bit.ly/3q2DlGd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Heiner Wedemeyer, MD, discusses HDV epidemiology beyond the United States, the features of HDV/HBV pathology, insights into screening and diagnostic approaches, key aspects of disease staging, new treatment options, and important remaining clinical questions regarding optimal management of HDV.Presenter:Heiner Wedemeyer, MDProfessor and ChairmanDepartment of Gastroenterology, Hepatology and EndocrinologyHannover Medical SchoolHannover, GermanyContent based on an online CME program supported by independent educational grants from AbbVie and Gilead Sciences, Inc. and developed in collaboration with the American Liver Foundation. Link to full program:https://bit.ly/3KmJvZt Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Episode 4 of this series features a conversation between a patient, Jason, and Paul Y. Kwo, MD, who discuss the particular challenges that can affect people with chronic hepatitis B seeking care in rural settings, including facing up to stigma, getting access to experienced medical practitioners, and searching for information and peer support.Presenter:Paul Y. Kwo, MDProfessor of MedicineDirector of HepatologyStanford University School of MedicinePalo Alto, CaliforniaContent based on an online CME program supported by independent educational grants from AbbVie and Gilead Sciences.Link to full program:https://bit.ly/3KmJvZt Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode from the series “Key Decisions in HIV Care,” Latesha Elopre, MD, MSPH, and Karine Lacombe, MD, PhD, discuss important considerations for PrEP in cisgender men and transgender women, including:Discussion of the PrEP gap and racial and gender disparities in PrEP access CDC, EACS, and WHO guidance on PrEP eligibility PrEP regimens currently recommended for adults and adolescents including FTC/TDF daily, FTC/TAF daily, and long-acting cabotegravir Data from clinical trials on the efficacy of FTC/TDF daily for men including Partners PrEP, TDF2, iPrEx, iPrEx OLE, and PROUD Data from the ANRS IPERGAY study on the use of FTC/TDF on demand Data from the DISCOVER trial on the use of FTC/TAF for PrEP Data from the HPTN 083 study on the use of long-acting cabotegravir as PrEP for cisgender men Clinical monitoring and considerations during PrEP usePresenters:Latesha Elopre, MDAssociate ProfessorDivision of Infectious DiseasesAssistant Dean of Diversity and InclusionGeneral Medical EducationUniversity of Alabama at BirminghamBirmingham, AlabamaKarine Lacombe, MD, PhDProfessorUMR-S1136Sorbonne UniversityHead, Infectious Diseases DepartmentSt Antoine Hospital, AP-HPParis, FranceContent based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.Follow along with the slides at:https://bit.ly/3uqPje3Link to full program:https://bit.ly/3q2DlGd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode from the series “Key Decisions in HIV Care,” Latesha Elopre, MD, MSPH, and Karine Lacombe, MD, PhD, discuss important considerations for PrEP in cisgender women, including: Discussion of the PrEP gap and racial and gender disparities in PrEP accessCDC, EACS, and WHO guidance on PrEP eligibilityPrEP regimens currently recommended for adults and adolescents including FTC/TDF daily, FTC/TAF daily, and long-acting cabotegravirData from phase III trials on the efficacy of FTC/TDF daily for women including Partners PrEP, TDF, VOICE, and FEM-PrEPPharmacokinetic data of FTC/TDF and FTC/TAF in the female genital tract and discussion of why on-demand dosing of FTC/TDF is not recommended in cisgender womenData and recommendations for the use of the dapivirine ring from ASPIRE and The Ring Study and their open-label extensions, DREAM and HOPEData from the HPTN084 study on the use of long-acting cabotegravir as PrEP for cisgender womenRecommendations for the use of PrEP during pregnancy and breastfeedingClinical monitoring and considerations during PrEP usePresenters:Latesha Elopre, MD, MSPHAssociate ProfessorDivision of Infectious DiseasesAssistant Dean of Diversity and InclusionGeneral Medical EducationUniversity of Alabama at BirminghamBirmingham, Alabama Karine Lacombe, MD, PhDProfessorUMR-S1136Sorbonne UniversityHead, Infectious Diseases DepartmentSt Antoine Hospital, AP-HPParis, France Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.Follow along with the slides at: https://bit.ly/36s2ovBLink to full program:https://bit.ly/3q2DlGd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Graham R. Foster, FRCP, PhD, and Paul Y. Kwo, MD, share lessons learned in the management of HCC and liver transplantation the COVID-19 era, including:• Global impact of HCC and strategies for maintaining HCC care in the COVID-19 era• Characteristics of liver transplant recipients in the COVID-19 era• Impact of COVID-19 pandemic period on liver transplant outcomes• Impact of liver transplant status on COVID-19 outcomes• Strategies for providing streamlined care for patients with liver cancer or liver transplantation in the COVID-19 eraPresenters:Graham R. Foster, FRCP, PhD Professor of Hepatology The Liver UnitConsultant Hepatologist Queen Mary University of LondonLondon, United KingdomPaul Y. Kwo, MDProfessor of Medicine Director of HepatologyStanford University School of MedicinePalo Alto, CaliforniaFollow along with the slides at:https://bit.ly/3HQ6dZ5Link to full program: https://bit.ly/3Bgyd5I Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jason Schafer, PharmD, MPH, explores key considerations for the use of long-acting injectable pre-exposure prophylaxis (PrEP).- Listen as he gives his perspectives on:- The FDA approval of long-acting cabotegravir for PrEP- Healthcare professionals’ clinical concerns with long-acting injectable antiretroviral therapy- Considerations for long-acting cabotegravir as PrEPDosing and administrationManaging missed dosesDiscontinuationDelays in HIV diagnoses found in the HPTN 083 study in men- CDC recommendations for HIV screening while receiving PrEPPresenter:Jason Schafer, PharmD, MPHProfessor and Vice ChairJefferson College of PharmacyThomas Jefferson UniversityPhiladelphia, Pennsylvania Follow along with the slides at: https://bit.ly/3wugMOCSee the entire program at: https://bit.ly/3q2DlGd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Hepatitis delta virus (HDV) is the most severe form of viral hepatitis and warrants new treatment options for better efficacy and tolerability. In part 2 of this 2-part podcast series, hear Heiner Wedemeyer, MD, and Cihan Yurdaydin, MD, discuss their thoughts on new and emerging treatment options for HDV and rational use of these new agents. Their discussion includes:Assembly inhibitors (eg, lonafarnib)Entry inhibitors (eg, bulevirtide)Interferon lambdaNucleic acid polymersSmall interfering RNA (siRNA) agentsPresenters: Heiner Wedemeyer, MDProfessor and ChairmanDepartment of Gastroenterology, Hepatology, and EndocrinologyHannover Medical SchoolHannover, GermanyCihan Yurdadin, MDProfessor and Chief Department of Gastroenterology and HepatologyKoç University Medical SchoolIstanbul, TurkeyLink to full program:https://bit.ly/365VUlG Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jeffrey Kwong, DNP, MPH, FAANP, FAAN, and Susan LeLacheur, DrPH, PA-C, AAHIVS, share insights on new HIV data from CROI 2022, including:Perinatal antiretroviral therapy exposureInvestigational formulation of long-acting contraception combined with pre-exposure prophylaxisMonitoring with long-acting cabotegravir for pre-exposure prophylaxisMyocardial infarction risk by HIV statusPresenters:Jeffrey Kwong, DNP, MPH, FAANP, FAANProfessorDivision of Advanced Nursing PracticeRutgers School of NursingNewark, New JerseyNurse PractitionerGotham Medical GroupNew York, New YorkSusan LeLacheur, DrPH, PA-C, AAHIVSProfessorPA StudiesThe George Washington University School of Medicine and Health SciencesWashington, DCLink to full program: https://bit.ly/3tdkXfJ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Keith S. Kaye, MD, MPH; Lilian Abbo, MD, FIDSA; and Jason M. Pogue, PharmD, discuss HABP/VABP and gram-negative resistance including:Epidemiology and burden of nosocomial bacterial pneumoniaPatient-specific risk factors for MDR pathogensImproving outcomes with the use of antibiogramsRecommended empiric therapy for clinically suspected VABPAntimicrobial resistance in HABP/VABPAlgorithms for gram-negative organism antibiotic-susceptibility testingUsing rapid diagnostic tests for HABP/VABPNew antimicrobial agents for MDR gram-negative infections with discussion of the 2021 IDSA guidance, and the following studies:ASPECT-NP: ceftolozane/tazobactam vs meropenemREPROVE: ceftazidime/avibactam vs meropenemRESTORE-IMI-1 imipenem/cilastatin/relebactam vs colistin + imipenemRESTORE-IMI-2: imipenem/cilastatin/relebactam vs piperacillin/tazobactamAPEKS-NP: cefiderocol vs meropenemCREDIBLE-CR: cefiderocol vs best available therapyProgram Director:Keith S. Kaye, MD, MPHChiefDivision of Allergy, Immunology and Infectious DiseasesProfessor of MedicineRutgers Robert Wood Johnson Medical SchoolNew Brunswick, New JerseyFaculty:Lilian Abbo, MD, FIDSAAssociate Chief Medical Officer in Infectious DiseasesJackson Health SystemProfessor of Infectious DiseasesDepartment of Medicine & Miami Transplant InstituteUniversity of Miami Miller School of MedicineMiami, FloridaJason M. Pogue, PharmDClinical ProfessorDepartment of Clinical PharmacyUniversity of Michigan College of PharmacyInfectious Diseases Clinical PharmacistMichigan MedicineAnn Arbor, MichiganContent based on a CME program supported by an educational grant from Merck Sharp & Dohme Corp.Follow along with a downloadable slideset at:https://bit.ly/3CEop6hLink to full program https://bit.ly/3i781lf Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Fidelia Bernice, PharmD, and Jennifer Cocohoba, PharmD, share insights on new HIV data from CROI 2022, including:Islatravir tissue and plasma distribution after monthly oral dosingPharmacokinetics, safety, and acceptability of a tenofovir vaginal ringPrEP and Hormone Therapy in Transgender IndividualsAnticholinergic drug effects in older PWHAdherence in PWHPresenters:Fidelia Bernice, PharmDClinical Pharmacy Specialist, Infectious DiseasesDepartment of PharmacyUniversity of Maryland Medical CenterBaltimore, MarylandJennifer Cocohoba, PharmDProfessorDepartment of Clinical PharmacyUniversity of California, San FranciscoSan Francisco, CaliforniaLink to full program:https://bit.ly/3tdkXfJ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jordan J. Feld, MD, MPH, and Nancy Reau, MD, share lessons learned in the testing and treatment of viral hepatitis in the COVID-19 era, including:Global impact of the COVID-19 pandemic on viral hepatitis testing and linkage to careImpact of COVID-19 pandemic on testing and treatment in the United States and CanadaInnovative strategies to improve linkage to care of patients with viral hepatitis during the COVID-19 pandemicPresenters:Jordan J. Feld, MD, MPHProfessor of MedicineUniversity of TorontoHepatologistToronto Centre for Liver DiseaseSandra Rotman Centre for Global HealthToronto, CanadaNancy Reau, MDProfessor of MedicineChief, Section of HepatologyAssociate Director, Solid Organ TransplantationRichard B. Capps Chair of HepatologyRush University Medical CenterChicago, IllinoisFollow along with the slides at:https://bit.ly/3HQ6dZ5Link to full program:https://bit.ly/3Bgyd5I Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jason Schafer, PharmD, MPH, explores the data for long-acting injectable pre-exposure prophylaxis (PrEP).Listen as he gives his perspectives on the:PrEP pipeline and the importance of having options for patients with differing preferencesFDA approval of long-acting cabotegravir for PrEPHPTN 083 and 084 studies of long-acting cabotegravir for PrEP compared with oral emtricitabine/tenofovir disoproxil fumarateSafety data on long-acting cabotegravir for PrEPCDC recommendations on the management of injection-site reactions with cabotegravir for PrEPPresenter:Jason Schafer, PharmD, MPHProfessor and Vice ChairJefferson College of PharmacyThomas Jefferson UniversityPhiladelphia, Pennsylvania Follow along with the slides at:https://bit.ly/3tbvEPKSee the entire program at: https://bit.ly/3q2DlGd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Daniel R. Kuritzkes, MD, and David A. Wohl, MD, discuss new HIV data from CROI 2022, including:Prevention strategiesLA therapiesSecond-line therapiesThe VISEND study comparing dolutegravir-based antiretroviral therapy (ART) vs protease inhibitor–based ART for second-line therapyThe NADIA study comparing dolutegravir with darunavir/ritonavir and tenofovir disoproxil fumarate with zidovudine for second-line therapyComorbidities and cureACTG A5324 (InMIND) study of ART intensification for cognitive impairment in people with HIVIMPAACT P1107 case of patient with loss of HIV-1–specific antibody response and viral detection following CCR5∆32/∆32 cord/haploidentical transplantDaniel R. Kuritzkes, MDChief, Division of Infectious DiseasesBrigham and Women’s HospitalHarriet Ryan Albee Professor of MedicineHarvard Medical SchoolBoston, MassachusettsDavid A. Wohl, MDProfessor of MedicineSchool of MedicineSite Leader, Global Infectious Diseases Clinical Trials UnitUniversity of North Carolina at Chapel HillContent based on a CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare.Follow along with an expanded slideset at:https://bit.ly/3CItz0ZLink to full program:https://bit.ly/3tSpdAx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jason Schafer, PharmD, MPH, explores recommendations and data on managing antiretroviral therapy (ART) in the inpatient setting.Listen as he gives his perspectives on:Antiretroviral stewardship to prevent medication errors in the inpatient setting and at transitions of careRenal and hepatic dosing considerations for ARTDrug–drug interaction considerations between ART and medications commonly encountered in the inpatient settingAntiretroviral food effectsAdministration of antiretrovirals in persons with swallowing difficultiesPresenter:Jason Schafer, PharmD, MPHProfessor and Vice ChairJefferson College of PharmacyThomas Jefferson UniversityPhiladelphia, Pennsylvania Follow along with the slides at:https://bit.ly/36h5tOCSee the entire program at: https://bit.ly/3q2DlGd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Hepatitis delta virus (HDV) only exists in patients with hepatitis B virus (HBV) coinfection. In part 1 of this 2-part podcast series, hear Heiner Wedemeyer, MD, and Cihan Yurdaydin, MD, discuss their thoughts on serologic testing for both HDV and HBV and steps to take in monitoring, treating, and reassessing HBV in patients coinfected with HDV.Presenters:Heiner Wedemeyer, MDProfessor and ChairmanDepartment of Gastroenterology, Hepatology, and EndocrinologyHannover Medical SchoolHannover, GermanyCihan Yurdaydin, MDProfessor and Chief, Department of Gastroenterology and HepatologyKoç University Medical SchoolIstanbul, TurkeyLink to full program:https://bit.ly/365VUlG Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Episode 3 of this series features Anna Cristina L. dela Cruz, MD, in conversation with patient Melody Cheng about Melody’s decision to start hepatitis B virus (HBV) antiviral therapy during pregnancy. This podcast also discusses recommended approaches to preventing HBV transmission from mother to child, current recommendations on starting treatment for chronic HBV infection, and the issues around stopping treatment.Presenter:Anna Christina L. dela Cruz, MDAssociate ProfessorDivision of Digestive Diseases and NutritionDepartment of Internal MedicineUniversity of KentuckyLexington, KentuckyContent based on an online CME program supported by independent educational grants from AbbVie and Gilead Sciences.Link to full program: https://bit.ly/3KmJvZt Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Treatment options for hepatitis delta virus (HDV) are lacking, but many exciting agents are under investigation. Hear Drs Nancy Reau and Stefan Zeuzem discuss their thoughts on up-and-coming agents for treating HDV, and explore what questions need answering to most effectively use currently available and emerging therapies, which include:BulevirtideInterferon λLonafarnibPresenters:Nancy Reau, MDProfessor of MedicineChief, Section of HepatologyAssociate Director, Solid Organ TransplantationRichard B. Capps Chair of HepatologyRush University Medical CenterChicago, IllinoisStefan Zeuzem, MDProfessor of MedicineChief, Department of Medicine IJW Goethe University HospitalFrankfurt, GermanyLink to full program:https://bit.ly/3tlxa0H Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In episode 2 of this series, tune in to a conversation between Robert G. Gish, MD, and patient advocate Jacki Chen, PhD, about the potential benefits of simplifying our approach to treating patients with chronic hepatitis B. The conversation focuses on the stigma many patients experience following diagnosis and how access to treatment may reduce this.Presenter:Robert G. Gish, MDProfessor of MedicineLoma Linda UniversityLoma Linda, CaliforniaAdjunct Professor of Medicine Nevada School of Medicine Las Vega, NevadaClinical ProfessorUniversity of Nevada Reno School of MedicineClinical ProfessorUniversity of California Skaggs School of Pharmacy and Pharmaceutical SciencesSan Diego, CaliforniaMedical DirectorHepatitis B FoundationWashington, DCContent based on an online CME program supported by independent educational grants from AbbVie and Gilead Sciences.Link to full program:https://bit.ly/3lSkSui Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Drs Norah Terrault, MD, MPH, and Grace LH Wong, MD, share lessons learned in the care of patients with hepatitis B virus (HBV) in the COVID-19 era, including:HBV cascade of care before vs during the pandemicInnovative strategies to improve HBV diagnosis and linkage to careLessons learned in telemedicineElimination through vaccinationManagement of HBV and COVID-19 coinfectionManagement of elevated liver enzymes in COVID-19Presenters:Norah Terrault, MD, MPHProfessor of MedicineChief of Gastrointestinal and Liver DiseasesUniversity of Southern CaliforniaLos Angeles, CaliforniaGrace LH Wong, MDProfessorDirector, Medical Data Analytics Centre (MDAC)Deputy Director, Center for Liver Health Assistant Dean (Learning Experience), Faculty of MedicineThe Chinese University of Hong Kong Honorary ConsultantDivision of Gastroenterology and HepatologyDepartment of Medicine and TherapeuticsPrince of Wales HospitalHong KongFollow along with the slides at:https://bit.ly/3HQ6dZ5Link to full program:https://bit.ly/3Bgyd5I Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Sharon R. Lewin, AO, FRACP, PhD, FAHMS, discusses what is known about the SARS-CoV-2 omicron variant, including:Transmissibility and infectiousness Immune evasionDisease severity Risks of hospitalization and death Vaccine effectiveness 2- vs 3-dose vaccine effectivenessT-cell responsePresenter: Sharon R. Lewin, AO, FRACP, PhD, FAHMSDirector, The Peter Doherty Institute for Infection and ImmunityProfessor of Infectious DiseasesUniversity of MelbourneConsultant Infectious Diseases PhysicianAlfred Hospital and Royal Melbourne HospitalMelbourne, AustraliaReview the downloadable slidesets at:https://bit.ly/32tp2BThttps://bit.ly/3JKyNLW Link to full program:https://bit.ly/3Ix8uZg Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In episode 6 of an ongoing series of sharing sessions between a physician and patient, Tarik Asselah, MD, PhD, and his patient, who is living with chronic hepatitis B (CHB), discuss:Importance and goals of hepatitis B virus (HBV) treatment, with a call for broader access to treatment worldwideScreening for HBV, especially given the frequency of asymptomatic diseaseHBV vaccination as a preventive measureLiving a healthy life and maintaining hope while living with CHBPresenter: Tarik Asselah, MD, PhD Professor of MedicineDepartment of HepatologyHôpital BeaujonUniversité de ParisClichy, FranceContent based on an online CME program supported by an independent educational grant from Gilead Sciences.Link to full program:https://bit.ly/3565S64 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Mark S. Sulkowski, MD, explores recommendations and data on treating HIV and hepatitis C virus (HCV) in patients who are coinfected.Listen as he gives his perspectives on:Prioritization of both HIV and HCV treatmentEfficacy of HCV direct-acting antivirals in people with HIVAmerican Association for the Study of Liver Diseases/Infectious Diseases Society of America recommendations for first-line HCV treatment in HIV/HCV coinfectionInternational guidance on first-line antiretroviral therapyHIV/HCV drug–drug interactionsThe Swiss HCVree Trial of HCV treatment as prevention in men who have sex with men with HIVDependence of HCV elimination on the HIV care continuum for people who are HIV/HCV coinfectedPresenter:Mark S. Sulkowski, MDProfessor of MedicineMedical Director, Viral Hepatitis CenterChief, Infectious DiseaseJohns Hopkins Bayview Medical CenterJohns Hopkins University School of MedicineBaltimore, Maryland Follow along with the slides at: https://bit.ly/3oUi29gLink to full program:https://bit.ly/3fOl0XX Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Mark S. Sulkowski, MD, discusses his recommended approach for managing nonalcoholic steatohepatitis in patients with HIV, including recognizing nonalcoholic steatohepatitis, recommending lifestyle interventions, and considering pharmacologic approaches. Presenter:Mark S. Sulkowski, MDProfessor of MedicineMedical Director, Viral Hepatitis CenterChief, Infectious DiseaseJohns Hopkins Bayview Medical CenterJohns Hopkins University School of MedicineBaltimore, MarylandContent based on an online CME program supported by an educational grant from Theratechnologies Inc.Link to full program: https://bit.ly/3Gk7juJ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Robert G. Gish, MD, and Pietro Lampertico, MD, PhD, share lessons learned in the care of patients coinfected with hepatitis B virus and hepatitis delta virus (HDV), including:Burden of HDV infectionChronic HDV infection and comorbiditiesImpact of COVID-19 on care of patients with chronic hepatitis BScreening for HDV and which assays to useScreening for viral hepatitis at a COVID-19 vaccination sitePresenters:Robert G. Gish, MD, FAASLD, AGAF, FASTProfessor of MedicineLoma Linda UniversityLoma Linda, CaliforniaClinical ProfessorUniversity of Nevada Reno School of MedicineReno, NevadaUniversity of California Skaggs School of Pharmacy and Pharmaceutical SciencesSan Diego, CaliforniaMedical DirectorHepatitis B FoundationWashington, DCPietro Lampertico, MD, PhDProfessor of GastroenterologyDirector, Division of Gastroenterology and HepatologyIRCCS Ca Granda Policlinico HospitalUniversity of MilanMilan, ItalyFollow along with the slides at:https://bit.ly/3HQ6dZ5Link to full program: https://bit.ly/3Bgyd5I Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode from the series “Key Decisions in HIV Care,” Jonathan Appelbaum, MD, FACP, AAHIVS, and Jens D. Lundgren, MD, DMSc, discuss important considerations for antiretroviral therapy (ART) use in older patients with renal and hepatic impairment.European AIDS Clinical Society guideline screening recommendations for kidney disease in people with HIVAntiretroviral dose adjustment recommendations based on estimated glomerular filtration rateData on the use of full-dose lamivudine with renal impairmentData on the use of 2-drug nucleos(t)ide reverse-transcriptase inhibitor–sparing ART regimens, including GEMINI-1 and -2, TANGO, and SALSA for dolutegravir/lamivudine; SWORD-1 and -2 for dolutegravir/lamivudine; and ATLAS and FLAIR for long-acting cabotegravir plus rilpivirineUS Department of Health and Human Services recommendations on the use of ART agents with hepatic impairmentRecommendations from the American Gastroenterological Association on screening and diagnosis of nonalcoholic fatty liver disease (NAFLD)Prevalence of NAFLD, nonalcoholic steatohepatitis, and liver fibrosis in people with HIVOverlapping risk factors between HIV and NAFLDPresenters:Jonathan Appelbaum, MD, FACP, AAHIVSLaurie L. Dozier Jr, MD, Education DirectorProfessor of Internal MedicineChair, Department of Clinical SciencesFlorida State University College of MedicineTallahassee, Florida Jens D. Lundgren, MD, DMScProfessorRigshospital, University of CopenhagenDirectorCentre of Excellence for Health, Immunity and Infection (CHIP)Rigshospital, University of CopenhagenCopenhagen, Denmark Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.Follow along with the slides at:https://bit.ly/3gAsu19Link to full program:https://bit.ly/3fOl0XX Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jürgen K. Rockstroh, MD, and Giada Sebastiani, MD, discuss key strategies to appropriately screen for, identify, and manage nonalcoholic steatohepatitis in persons with HIV. They also answer pressing questions from healthcare professionals.Presenters: Jürgen K. Rockstroh, MDProfessor of MedicineUniversity Hospital BonnDepartment of Medicine IBonn, GermanyGiada Sebastiani, MDAssociate Professor of MedicineMcGill University Health CentreDivision of Gastroenterology and Hepatology and Division of Infectious DiseasesClinician ScientistResearch Institute of McGill University Health CentreMontreal, Quebec, CanadaContent based on an online CME program supported by an educational grant from Theratechnologies Inc.Link to full program:https://bit.ly/363orZ9 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jürgen K. Rockstroh, MD, discusses his recommended approach for diagnosing nonalcoholic steatohepatitis in patients with HIV, the value of noninvasive diagnostic tests such as serum biomarkers and elastography, and how timely nonalcoholic fatty liver disease assessment and metabolic risk factor determination can result in early interventions.Presenter:Jürgen K. Rockstroh, MDProfessor of MedicineUniversity Hospital BonnDepartment of Medicine IBonn, GermanyContent based on an online CME program supported by an educational grant from Theratechnologies Inc.Link to full program:https://bit.ly/3Gk7juJ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, John D. Baxter, MD, explores recommendations and data on the use of proviral DNA genotyping to inform antiretroviral therapy (ART) choice for patients who are treatment experienced.Listen as he gives his perspectives on:US Department of Health and Human Services guideline recommendations on the use of proviral DNA genotypingUS Department of Health and Human Services guideline recommendations and supporting data on switching ART with viral suppression and underlying drug resistanceStudy 380-4030 on outcomes with bictegravir- and dolutegravir-based ART in patients with preexisting nucleos(t)ide reverse-transcriptase inhibitor resistanceThe BRAAVE 2020 study on switching to bictegravir/emtricitabine/tenofovir alafenamide in Black persons with HIV, some of whom had baseline ART resistanceBetween-class ART switches with underlying resistanceSusceptibility of tenofovir disoproxil fumarate and abacavir with thymidine analogue mutationsPresenter:John D. Baxter, MDProfessor of MedicineDivision of Infectious DiseasesDepartment of PathologyCooper Medical School of Rowan UniversityHead, Division of Infectious DiseasesCooper University Health CareCamden, New JerseyFollow along with the slides at:https://bit.ly/3HmkSLcSee the entire program at: https://bit.ly/3fOl0XX Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Rageshri Dhairyawan, MBBS, BSc, FRCP, DipGUM, DFSRH, DipHIV, and Solange L. Baptiste, ScM, discuss the burden of HIV among BIPOC and migrant communities and key strategies to reduce racial disparities in HIV care globally:Disproportionate impact of HIV among BIPOC communities and migrant populations globallyBarriers to HIV testing, prevention, and treatment services among BIPOC communities and migrant populationsStrategies to overcome health system–based and provider-based barriers to engagement with HIV careRageshri Dhairyawan, MBBS, BSc, FRCP, DipGUM, DFSRH, DipHIVHonorary Senior Lecturer in HIV MedicineBlizard Institute, Faculty of Medicine and DentistryQueen Mary University of LondonConsultant Physician in HIV MedicineDepartment of Infection and ImmunityBarts Health NHS TrustLondon, United KingdomSolange L. Baptiste, ScMExecutive DirectorInternational Treatment Preparedness CoalitionBryanston, South AfricaContent based on a CME program supported by educational grants from AbbVie; Gilead Sciences, Inc.; and Janssen Therapeutics, Division of Janssen Products, LP To follow along, download the slides at:https://bit.ly/3ngDrsvLink to full program:https://bit.ly/3gh6WXj Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, John D. Baxter, MD, explores recommendations and data on choosing antiretroviral therapy with transmitted drug resistance.Listen as he gives his perspectives on:Initial response to antiretroviral therapy during primary HIV infection with baseline resistanceData from the START study on treatment-naive patients with transmitted drug resistance by region and drug classRecommendations from the US Department of Health and Human Services and International AIDS Society–USA guidelines on baseline genotype testing for integrase strand transfer inhibitor resistanceConsiderations for the use of second-generation integrase strand transfer inhibitors and darunavir with transmitted drug resistanceCases of transmitted multidrug-resistant HIV in patients receiving pre-exposure prophylaxisPresenter:John D. Baxter, MDProfessor of MedicineDivision of Infectious DiseasesDepartment of PathologyCooper Medical School of Rowan UniversityHead, Division of Infectious DiseasesCooper University Health CareCamden, New JerseyFollow along with the slides at:https://bit.ly/3u7pjWqSee the entire program at: https://bit.ly/3fOl0XX Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The SARS-CoV-2 omicron variant has affected which of our COVID-19 treatment strategies are currently effective, with some expected to maintain their efficacy and some expected to lose their efficacy. In this episode, Arthur Kim, MD, discusses the effects of the SARS-CoV-2 omicron variant on many of the COVID-19 approved, authorized, and investigational treatment options, including:Direct-acting, small-molecule antiviral agents such as molnupiravir, nirmatrelvir + ritonavir, and remdesivirMonoclonal antibody treatments such as bamlanivimab + etesevimab, casirivimab + imdevimab, cilgavimab + tixagevimab, regdanvimab, and sotrovimabPresenter:Arthur Kim, MDAssociate ProfessorDepartment of MedicineHarvard Medical SchoolDirector, Viral Hepatitis ClinicDivision of Infectious DiseasesMassachusetts General HospitalBoston, MassachusettsReview the downloadable slidesets at:https://bit.ly/3FXc90whttps://bit.ly/32tp2BTLink to full program: https://bit.ly/3Ix8uZg Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Samantha V. Hill, MD, MPH, and David Malebranche, MD, MPH, examine key facilitators to tackling racial inequities in HIV care, including:Barriers to HIV testing, prevention, and treatment services in BIPOC communities and migrant populationsFacilitators to HIV testing, prevention, and treatment services in BIPOC communities and migrant populationsStrategies to overcome health system–based and healthcare professional–based barriers to engagement with HIV careSamantha V. Hill, MD, MPHAssistant ProfessorDivision of Adolescent MedicineDepartment of PediatricsThe University of Alabama at BirminghamBirmingham, AlabamaDavid Malebranche, MD, MPHInternal Medicine PhysicianHIV/Sexual Health SpecialistAIDS Healthcare Foundation (AHF) Medical ClinicAtlanta, GeorgiaContent based on a CME program supported by educational grants provided by AbbVie; Gilead Sciences, Inc.; and Janssen Therapeutics, Division of Janssen Products, LP To follow along, download the slides at:https://bit.ly/3ngDrsvLink to full program:https://bit.ly/3gh6WXj Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode from the series “Key Decisions in HIV Care,” Daria Podlekareva, MD, PhD, and Mark S. Sulkowski, MD, discuss important considerations for ART use in patients with coinfections, including:DHHS testing and treatment recommendations for HBV in patients with HIVData suggesting that tenofovir alone may not suppress HBV in all PWHData from NA-ACCORD showing that incomplete HBV DNA suppression is associated with HCC in patients with HIV/HBVData for the use of entecavir as an add-on therapy if an HIV ART regimen is not HBV activeData showing that lamivudine alone is associated with resistance in patients with HIV/HBVDiscussion of HBV management in the setting of 2-drug regimens for HIV if the patient is coinfectedRecommendations from the DHHS, EACS, and WHO to start ART as soon as possible in patients with TB/HIV coinfectionData from the SAPiT, ACTG A5221 STRIDE, and CAMELIA studies to show the benefits of early ART in patients with TB/HIVRecommendations from the EACS guidelines on what ART regimens are recommended with TB/HIVDrug-drug interaction considerations between ART and TB treatmentDiscussion of the prevention and management of TB-associated IRISPresenters:Daria Podlekareva, MD, PhDCentre of Excellence for Health, Immunity and Infection (CHIP)Rigshospital, University of CopenhagenCopenhagen, Denmark Mark S. Sulkowski, MDProfessor of MedicineMedical Director, Viral Hepatitis CenterChief, Infectious DiseaseJohns Hopkins Bayview Medical CenterJohns Hopkins University School of MedicineBaltimore, MarylandContent based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.Follow along with slides:https://bit.ly/3zHySMOSee the entire program at:https://bit.ly/2TXTYWx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Karen Ha, MD, explores recommendations and data on the role of PIs in current practice.Listen as she gives her perspectives on:DHHS guideline recommendations on the use of PI-based ARTData from the DIAMOND study on the use of boosted DRV for rapid initiationData from the EARNEST and NADIA studies on the use of PI-based ART with NRTI resistanceConsiderations for the use of PIs in patients with cardiovascular risk, including data from the D:A:D studyKey drug–drug interaction considerations with the use of PIsPresenter:Karen Ha, MDAssistant Professor of MedicineDivision of Infectious DiseasesDepartment of MedicineCooper University HospitalCooper Medical School of Rowan UniversityCamden, New JerseyFollow along with the slides at: https://bit.ly/3zvO6EBSee the entire program at:https://bit.ly/2TXTYWx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Renslow Sherer, MD, discusses key data on COVID-19 oral antiviral agents—molnupiravir and nirmatrelvir (PF-07321332) plus ritonavir—for nonhospitalized adults with mild to moderate COVID-19, including:EPIC-HR study of nirmatrelvir (PF-07321332) plus ritonavirSafety dataEfficacy dataMOVe-OUT study of molnupiravirSafety dataEfficacy dataRoles in treatment of COVID-19Timing of treatmentPresenter:Renslow Sherer, MDDirector, International HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisReview the downloadable slideset at:https://bit.ly/31wi1QiLink to full program:https://bit.ly/3EH2485 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Karen Ha, MD, explores recommendations and data on the role of NNRTIs in current practice.Listen as she gives her perspectives on:DHHS guideline recommendations on the use of NNRTI-based ARTWeight gain data from the ADVANCE study, DRIVE-AHEAD, DRIVE-FORWARD, DRIVE-SHIFT, and a multivariate analysis of weight gain on ARTKey food effects and drug–drug interaction considerations with the use of NNRTIsPresenter:Karen Ha, MDAssistant Professor of MedicineDivision of Infectious DiseasesDepartment of MedicineCooper University HospitalCooper Medical School of Rowan UniversityCamden, New JerseyFollow along with the slides at: https://bit.ly/3G2PS2pSee the entire program at:https://bit.ly/2TXTYWx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Christian R. Pollard provides his perspectives as an individual taking daily oral HIV PrEP, including factors he considered in the decision to use PrEP, his experience with taking PrEP (daily pills and periodic laboratory testing), and his thoughts on what opportunities future PrEP options may offer.Presenter:Christian R. PollardContent based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.Link to full program:https://bit.ly/3AFvsZY Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode from the series “Key Decisions in HIV Care,” W. David Hardy, MD, and Josep M. Llibre, MD, PhD, discuss important considerations for ART use in the context of virologic failure and resistance, including:A discussion of the definitions of the following: highly treatment experienced, complex ART, multidrug-resistant HIV, and limited treatment optionsThe scope of the problem, including data from the CNICS cohortDHHS and EACS guideline recommendations on the management of virologic failure and drug resistance, including recommendations for the use of genotypic and phenotypic genotyping and proviral DNA sequencingConstruction of an optimized background regimen with discussion of the OPTIONS, DAWNING, NADIA, and VIKING-3 trialsNovel treatment options, including ibalizumab and data from TMB-301/-311, fostemsavir and data from BRIGHTE, and lenacapavir and data from CAPELLAPresenters:W. David Hardy, MDScientific and Medical ConsultantAdjunct Clinical Professor of MedicineDivision of Infectious DiseasesKeck School of Medicine of USCLos Angeles, CaliforniaJosep M. Llibre, MD, PhDS­enior Consultant Physician and Clinical ResearcherInfectious Disease and “Fight against AIDS and Infectious Diseases Foundation”Hospital Universitari Germans Trias i PujolBadalonaBarcelona, Spain Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.Follow along with the slides at: https://bit.ly/3z9AtL0Link to full program:https://bit.ly/2TXTYWx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Hear insights from 3 faculty experts as they present emerging data and guidelines and engage in discussion on patient-centered ART selection for people with HIV.Topics include assessing treatment options; individualizing ART for women of childbearing potential and during pregnancy, patients with OIs, and during the COVID-19 pandemic; and new data on investigational ART strategies. Learn how to:Apply the results of recent clinical studies and evolving treatment guidelines on the timing and choice of first-line ART and switch strategies and managing treatment-experienced patients with HIVIntegrate individual patient factors such as drug–drug interactions, comorbidities, pregnancy status, adherence, and dosing preferences when selecting optimal ARTAppropriately counsel patients regarding the anticipated clinical role of new and investigational ART regimens in individualized carePresenters:Chloe Orkin, MBChB, FRCP, MDProfessor of HIVQueen Mary, University of LondonConsultant PhysicianLead for HIV ResearchBarts Health NHS TrustThe Royal London HospitalLondon, United KingdomJean-Michel Molina, MD, PhDHead of the Department ofInfectious DiseasesSaint-Louis Hospital, Assistance-Publique Hôpitaux de ParisProfessor of Infectious DiseasesUniversity of ParisParis, FranceCristina Mussini, MDHead of Department of Infectious Diseases and Tropical MedicineFull Professor of Infectious DiseasesInfectious Diseases Clinics University HospitalUniversity of Modena and Reggio EmiliaReggio Emilia, ItalyFollow along with the slides at: https://bit.ly/329c8ZPSee the entire program at:https://bit.ly/3FkRofM Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode from the series “Key Decisions in HIV Care,” Jonathan Appelbaum, MD, FACP, AAHIVS, and Jens D. Lundgren, MD, DMSc, discuss important considerations for ART use in older PWH, including:DHHS, EACS, IAS, and WHO recommendations for first-line ARTVirologic outcomes for older PWH in clinical trials and results from the HealthHIV Second Annual National SurveyPolypharmacy and its potential consequences, including common non-ARV medications prescribed in the VACS cohort, drug–drug interactions with common concomitant medications, common comorbidities in older PWH, and drug–disease state interactions including renal and hepatic impairmentCardiovascular risk considerations including data from the D:A:D study and RESPOND cohort and lipid changes in the TANGO study of switching to DTG/3TC from TAF-based ARTPresenters:Jonathan Appelbaum, MD, FACP, AAHIVSLaurie L. Dozier Jr, MD, Education DirectorProfessor of Internal Medicine Chair, Department of Clinical SciencesFlorida State University College of MedicineTallahassee, Florida Jens D. Lundgren, MD, DMScProfessorRigshospital, University of CopenhagenCopenhagen, DenmarkDirectorCentre of Excellence for Health, Immunity and Infection (CHIP)Rigshospital, University of CopenhagenCopenhagen, Denmark Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.Follow along with the slides at:https://bit.ly/3miT6qHSee the entire program at: https://bit.ly/2TXTYWx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Hepatitis delta is the most severe form of viral hepatitis, and many patients remain undiagnosed. In this episode, Maria Buti, MD, and Robert G. Gish, MD, discuss the prevalence and severity of hepatitis delta. Hear their personal experiences from the clinic and their call to action for universal screening of patients with hepatitis B for coinfection with hepatitis delta.Presenters:Maria Buti, MDProfessor of MedicineHospital Universitario Vall d'HebronBarcelona, SpainRobert G. Gish, MDProfessor of MedicineLoma Linda UniversityLoma Linda, CaliforniaMedical DirectorHepatitis B FoundationWashington, DCLink to full program:https://bit.ly/3E9xKSx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Milena Murray, PharmD, MSc, BCIDP, AAHIVP, explores recommendations and data on patient specific factors associated with LA CAB plus RPV failure.Listen as she gives her perspectives on:LA CAB plus RPV pharmacokinetic dataDHHS guideline recommendations on which patients can be considered for LA CAB plus RPVData from the ATLAS, FLAIR, and ATLAS-2M studies on patients with virologic failure and the factors that may have contributedPresenter:Milena Murray, PharmD, MSc, BCIDP, AAHIVPAssociate ProfessorPharmacy PracticeMidwestern University College of PharmacyDowners Grove CampusDowners Grove, IllinoisHIV/ID Clinical PharmacistNorthwestern Memorial HospitalChicago, Illinois Follow along with the slides at: https://bit.ly/3EfaSRXSee the entire program at: https://bit.ly/2TXTYWx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.